Eeva-Maija Kinnunen

TL;DR: The Trifecta aortic bioprosthesis is associated with a higher occurrence of repeat aorti valve replacement for structural valve failure compared to the Perimount Magna Ease bioposthesis, and further comparative studies with echocardiographic data on structural valve deterioration are needed to confirm these findings.

TL;DR: PVE is rare, and its risk is similar after TAVR and SAVR, and in competing risk analysis there was no significant difference in the risk of PVE between patients with TAVr and S AVR over an eight-year observational period.

TL;DR: This comparative effectiveness cohort study examines 30-day and 3-year survival among Finnish patients with aortic stenosis at low operative risk who underwent transcatheter aorto-surgical valve replacement compared with surgical aorta replacement.

TL;DR: In Finland, the introduction of TAVR has led to an increase in the invasive treatment of severe aortic stenosis, which was accompanied by improved early outcomes after both SAVR and T AVR, which demonstrated that transcatheter aorti valve replacement has fulfilled its previously unmet clinical needs and has surpassed surgical aortsic valve replacement as the most common invasive treatment for aorta stenosis.

TL;DR: The findings suggest that severe aortic stenosis patients should be referred for invasive treatment before the development of clinically evident heart failure, and recent AHF is associated with increased risk of mortality and morbidity after SAVR and TAVR.